Enhanced chondrogenic differentiation of iPS cell-derived mesenchymal stem/stromal cells via neural crest cell induction for hyaline cartilage repair

Front Cell Dev Biol. 2023 May 10:11:1140717. doi: 10.3389/fcell.2023.1140717. eCollection 2023.

Abstract

Background: To date, there is no effective long-lasting treatment for cartilage tissue repair. Primary chondrocytes and mesenchymal stem/stromal cells are the most commonly used cell sources in regenerative medicine. However, both cell types have limitations, such as dedifferentiation, donor morbidity, and limited expansion. Here, we report a stepwise differentiation method to generate matrix-rich cartilage spheroids from induced pluripotent stem cell-derived mesenchymal stem/stromal cells (iMSCs) via the induction of neural crest cells under xeno-free conditions. Methods: The genes and signaling pathways regulating the chondrogenic susceptibility of iMSCs generated under different conditions were studied. Enhanced chondrogenic differentiation was achieved using a combination of growth factors and small-molecule inducers. Results: We demonstrated that the use of a thienoindazole derivative, TD-198946, synergistically improves chondrogenesis in iMSCs. The proposed strategy produced controlled-size spheroids and increased cartilage extracellular matrix production with no signs of dedifferentiation, fibrotic cartilage formation, or hypertrophy in vivo. Conclusion: These findings provide a novel cell source for stem cell-based cartilage repair. Furthermore, since chondrogenic spheroids have the potential to fuse within a few days, they can be used as building blocks for biofabrication of larger cartilage tissues using technologies such as the Kenzan Bioprinting method.

Keywords: cartilage; cell-based therapy; chondrocytes; chondrogenesis; induced mesenchymal stem/stromal cells; induced pluripotent stem cells; mesenchymal stem/stromal cells; tissue engineering.

Grants and funding

This research was supported by the Incubation Program of Kyoto University, the Future Development Research Funding Program of Kyoto University Research Coordination Alliance, HEALIOS K.K., Ajinomoto Co., Inc., Takeda Pharmaceutical Company Limited, Japan Agency for Medical Research and Development (AMED) under Grant Number JP15bm0104001, grants-in-aid for scientific research from the Japan Society for the Promotion of Science (JSPS) (#16H05447), and iPS Cell Research Fund. This work was also supported by JST SPRING (grant number JPMJSP2110) to ZA.